Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ongoing trials with matrix metalloproteinase inhibitors.

P D Brown1

  • 1British Biotech Pharmaceuticals Ltd., Watlington Road, Oxford, OX4 6LY, UK. brownp@britbio.co.uk

Expert Opinion on Investigational Drugs
|November 4, 2000
PubMed
Summary

Matrix metalloproteinase inhibitors (MMPIs) show promise for treating diseases involving extracellular matrix degradation. While some trials faced setbacks, recent successes in gastric cancer trials indicate potential therapeutic benefits.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma.

Neuro-oncology·2025
Same author

Distribution of virulence determinants among antimicrobial-resistant and antimicrobial-susceptible <i>Escherichia coli</i> implicated in urinary tract infections.

Indian journal of medical microbiology·2016
Same author

Growth of single-layer boron nitride dome-shaped nanostructures catalysed by iron clusters.

Nanoscale·2016
Same author

Ag-catalysed cutting of multi-walled carbon nanotubes.

Nanotechnology·2016
Same author

Beta Cell Regenerating Potential of <i>Azadirachta indica</i> (Neem) Extract in Diabetic Rats.

The West Indian medical journal·2015

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Matrix metalloproteinase (MMP) dysregulation contributes to diseases marked by extracellular matrix degradation.
  • Matrix metalloproteinase inhibitors (MMPIs) are synthetic low molecular weight compounds designed to target MMP activity.

Purpose of the Study:

  • To review the clinical development and therapeutic potential of matrix metalloproteinase inhibitors (MMPIs).
  • To highlight recent successes and ongoing challenges in MMPI clinical trials across various diseases.

Main Methods:

  • Review of clinical trial data for MMPIs in cancer, rheumatoid arthritis, osteoarthritis, and macular degeneration.
  • Analysis of trial outcomes, including successes and halts, for specific MMPIs like marimastat, Ro 32-3555, and BAY 12-9566.

Related Experiment Videos

Main Results:

  • Clinical trials of MMPIs have yielded mixed results, with some trials halted (e.g., Ro 32-3555, BAY 12-9566).
  • Phase III trials of marimastat demonstrated efficacy in advanced gastric cancer, indicating therapeutic promise.
  • Ongoing trials with marimastat and other MMPIs (prinomastat, solimastat, BMS 275291, metastat, neovastat) are expected to yield further results.

Conclusions:

  • MMPIs represent a developing therapeutic class for diseases involving MMPs.
  • Future research will focus on specific MMP targeting to enhance efficacy and mitigate side effects like musculoskeletal issues.